The New Definition of Hypertension in 2017 ACC/AHA Hypertension Guideline May Boost Updating Strategies for Hypertension Prevention and Treatment
-
摘要: 高血压是导致中国居民心血管疾病发病和死亡风险增加首要且可改变的危险因素。由于大部分高血压患者病因不明,国内外高血压防治一直采用“以治为主”的策略,主要防治目标是提高高血压患者的知晓率、治疗率和控制率。因长期缺少遏制高血压发生的有效策略,我国高血压患病率在各个年龄组均不断增加,特别是在中青年人群有更明显的上升趋势。大量研究显示,血压值处于(130~139)/(80~89)mm Hg(1 mm Hg=0.133 kPa)的人群最高危。2017年美国多个专业协会联合发布了全球高血压诊断新标准,将原140/90 mm Hg的高血压诊断标准下调至130/80 mm Hg, 将发生高血压的高危人群直接纳入高血压范畴,并优先推荐生活方式的早期干预策略。本文对美国高血压诊断标准下调的动因和对我国高血压防治工作的借鉴意义进行分析和探讨。Abstract: Hypertension is the top modifiable cause for the incidence and mortality of cardiovascular disease in China. Because the etiology of hypertension is not clear in most of the patients, the current antihyperten-sive strategy focuses on its treatment rather than the prevention. The main goals are to increase the awareness rate, treatment rate, and control rate for patients with hypertension. Because of the lack of effective strategies to prevent the occurrence of hypertension, the prevalence rate of hypertension has been increasing in all age groups of adults in China, especially in young and middle-aged Chinese. Many studies show that people who have so-called prehypertension with systolic blood pressure of 130 to 139 mm Hg or diastolic blood pressure of 80 to 89 mm Hg have the highest risk of future hypertension. It is the first time in the world that the 2017 ACC/AHA hypertension guideline redefined hypertension by including prehypertension as stage 1 hypertension and recommended early lifestyle modification as the priority strategy for these patients. This article discussed the motivation and rationale of the new definition of hypertension issued by 2017 ACC/AHA, and analyzed the potential significance and positive impact on the development of the prevention and treatment of hypertension in China.
-
Key words:
- hypertension /
- diagnosis /
- criteria
利益冲突 无 -
[1] Zhao D, Liu J, Wang M, et al. Epidemiology of cardiovascular disease in China: current features and implications[J].Nat Rev Cardiol, 2018. doi: 10.1038/s41569-018-0119-4.[Epub ahead of print]. [2] 李立明.中国居民营养与健康状况调查报告之四: 2002高血压[M].北京: 人民卫生出版社, 2008: 23-35. [3] 国家卫生和计划生育委员会.中国居民营养与慢性病状况报告(2015)[R].北京: 人民卫生出版社, 2015: 83-85. [4] Wang Z, Chen Z, Zhang L, et al. Status of Hypertension in China: Results From the China Hypertension Survey, 2012-2015[J]. Circulation, 2018, 137: 2344-2356. doi: 10.1161/CIRCULATIONAHA.117.032380 [5] Reinikainen J, Laattilcainen T, Karvanen J, et al. Lifetime cumulative risk factors predict cardiovascular disease mortality in a 50-year follow-up study in Finland[J].Int J Epidemiol, 2015, 44:108-116. doi: 10.1093/ije/dyu235 [6] Liu K, Colangelo LA, Daviqlus ML, et al. Can Antihypertensive Treatment Restore the Risk of Cardiovascular Disease to Ideal Levels? The Coronary Artery Risk Development in Young Adults (CARDIA) Study and the Multi-Ethnic Study of Atherosclerosis (MESA)[J].J Am Heart Assoc, 2015, 4:e002275. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599509/ [7] Wang Y, Liu J, Wang W, et al. Lifetime risk for cardiovascular disease in a Chinese population: the Chinese Multi-Provincial Cohort Study[J]. Eur J Prev Cardiol, 2015, 22:380-388. doi: 10.1177/2047487313516563 [8] Wang Y, Liu J, Wang W, et al. Lifetime risk of stroke in young-aged and middle-aged Chinese population: the Chinese Multi-Provincial Cohort Study[J]. J Hypertens, 2016, 34:2434-2440. doi: 10.1097/HJH.0000000000001084 [9] Berry JD, Dyer A, Cai X, et al. Lifetime risk of cardiovascular disease[J]. N Engl J Med, 2012, 366:321-329. doi: 10.1056/NEJMoa1012848 [10] Stevens W, Peneva D, Li JZ, et al. Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China[J]. BMC Health Serv Res, 2016, 16:175. doi: 10.1186/s12913-016-1420-8 [11] Whelton PK, Carey RM, Aronow WS, et al.2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA /ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. Circulation, 2018, 138:e426-e483. https://pubmed.ncbi.nlm.nih.gov/29146533/ [12] Lu Y, Wang P, Zhou T, et al. Comparison of Prevalence, Awareness, Treatment, and Control of Cardiovascular Risk Factors in China and the United States[J]. J Am Heart Assoc, 2018, pii: e007462. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1161/JAHA.117.007462 [13] 李国奇, 刘静, 王薇, 等.中国35-64岁人群15年高血压发生风险预测研究[J].中华内科杂志, 2014, 53:265-268. doi: 10.3760/cma.j.issn.0578-1426.2014.04.004 [14] Qi Y, Han X, Zhao D, et al. Long-term cardiovascular risk associated with stage 1 hypertension defined by the 2017 ACC/AHA hypertension guideline[J]. JACC, 2018, 72:1201-1210. doi: 10.1016/j.jacc.2018.06.056 [15] Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013[J]. Lancet, 2016, 387:251-272. doi: 10.1016/S0140-6736(15)00551-6 [16] GBD 2016 cause of death collaborators. Global, regional and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet, 2017, 390:1151-1210. doi: 10.1016/S0140-6736(17)32152-9 [17] Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension[J]. Eur Heart J, 2018, 39:3021-3104. doi: 10.1093/eurheartj/ehy339 [18] 《中国高血压防治指南》修订委员会.中国高血压防治指南2018年修订版[J].心脑血管病防治, 2019, 9:1-45.
点击查看大图
计量
- 文章访问数: 571
- HTML全文浏览量: 77
- PDF下载量: 413
- 被引次数: 0